Takeda fails to gain FDA approval of diabetes drug alogliptin

04/25/2012 | MedCityNews.com

The FDA issued a complete response letter to Takeda Pharmaceutical for diabetes drug alogliptin as stand-alone treatment and in combination with Actos, another therapy by the drugmaker. Takeda, which licensed alogliptin from Furiex Pharmaceuticals, "will immediately request a meeting with the FDA to determine the appropriate next steps and [is] committed to addressing outstanding issues," said Thomas Harris, vice president of regulatory affairs at Takeda Global Research & Development Center.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr Statistician I (US/TB/00/0028/SL)
Santa Clara, CA
Food & Drug Associate
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA